Mirador Biomedical Inc.
Reducing risk in central venous access
This article was originally published in Start Up
During insertion of central venous catheters, physicians may unintentionally advance into an artery rather than the desired vein, an error that can cause serious complications, even death. Mirador Biomedical Inc. aims to improve the safety of central venous access with its Compass platform, battery-powered, pressure-measurement devices that can rapidly detect the difference in pressures between arteries and veins.
You may also be interested in...
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
Biomic Sciences recalls all lots of ION* Sinus Support and ION* Biome Sinus after FDE testing found microbial contamination causing reasonable probability of life-threatening adverse events for patients or people who recently underwent nasal or sinus surgery.